# Starton Holdings

Source: https://onco.cc/companies/starton-holdings/  
OnCo record `starton-holdings` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Starton is a New Jersey company that gives existing cancer medicines continuously, through a small pump under the skin or a slow-release tablet, instead of as a daily dose. Its lead product, STAR-LLD, is a continuous low-dose form of lenalidomide being tested in multiple myeloma that has come back or stopped responding.

## Summary

Starton Holdings, Inc., with principal executive offices and a laboratory in Paramus, New Jersey, filed a registration statement for its initial public offering with the SEC in 2026, with the Nasdaq symbol STA applied for. The filing describes a clinical-stage company whose platform delivers approved, off-patent medicines continuously, by ambulatory subcutaneous pump, oral controlled-release tablet or transdermal patch, to lower peak blood levels and improve tolerability, and says it is focused first on blood cancers.

Its lead programme STAR-LLD is continuous low-dose lenalidomide, the active ingredient of Revlimid, developed as a subcutaneous formulation (STAR-LLD-SC) and an oral controlled-release formulation (STAR-LLD-OCR) in parallel. The filing states that Phase 1 and 1b studies of STAR-LLD-SC in multiple myeloma are complete and that a Phase 2a study in relapsed or refractory multiple myeloma is under way; it also describes planned investigator-initiated trials with CAR-T cell therapies and T-cell engagers, the first with elranatamab supplied by Pfizer. A transdermal olanzapine patch for chemotherapy-induced nausea and vomiting is on hold. The company's operating subsidiary, Starton Therapeutics, is the sponsor of the registered trial NCT06087653.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Starton Holdings, Inc.; Starton Therapeutics; Starton Therapeutics, Inc; Starton Therapeutics Inc.
- HQ: Paramus, NJ
- Type: biotech
- Website: https://www.startontx.com/

## Notes

- Read from the S-1/A filed on EDGAR on 28 October 2026 (business summary, cover page and corporate information) on 4 November 2026. The offering had not priced when read, so no IPO round is recorded. Founding year not read.

## Sources

- SEC EDGAR: Starton Holdings S-1/A, October 2026: https://www.sec.gov/Archives/edgar/data/2049977/000121390026113388/ea0225405-18.htm
- Official website: https://www.startontx.com/
- ClinicalTrials.gov: continuous subcutaneous lenalidomide in multiple myeloma (NCT06087653): https://clinicaltrials.gov/study/NCT06087653

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [STAR-LLD](https://onco.cc/drugs/star-lld/)
- trials: [Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)](https://onco.cc/trials/nct06087653/)

---
JSON: https://onco.cc/api/v1/entities/starton-holdings.json